LeukoSite, Oxford Asymmetry Ltd. deal

The companies will develop small molecules that block a key step in the lymphocyte recruitment pathway in the intestines as treatments for inflammatory bowel disease (IBD). LeukoSite will retain worldwide rights to commercial products identified from the collaboration, pay a portion of research costs and make milestone payments to Oxford Asymmetry, which also will be eligible for royalties. ...